Cystic Fibrosis Treatments on the Horizon
Over 10 years ago, it was discovered that bacteria in people with CF is lower after nitric oxide inhalation
In 2004, a trial sponsored by Mallinckrodt to assess the safety and tolerability of inhaled nitric oxide in subjects with cystic fibrosis revealed, in addition to its original purpose, that bacterial sputum density (the amount of bacteria found in expelled phlegm) was reduced after nitric oxide inhalation.
Since the release of the 2004 study findings, more pharmaceutical companies and medical researchers have begun investigating the antimicrobial properties of nitric oxide and how those properties can be utilized to treat cystic fibrosis patients suffering with antibiotic-resistant P. aeruginosa lung infections.